UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Hematology Peer Reviewers

Michael Auerbach, MD, FACP

Clinical Professor of Medicine

Georgetown University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: AMAG Pharmaceuticals; Pharmacosmos [Restless legs syndrome, iron deficiency of pregnancy (Ferumoxytol, low molecular weight iron dextran)]. Consultant/Advisory Boards: AMAG; Pharmacosmos; Luitpold/American Regent [Moderate to severe iron deficiency (Low molecular weight iron dextran)].

Joel S Bennett, MD

Professor of Medicine, Hematology-Oncology Division

University of Pennsylvania

Disclosure: Nothing to disclose

Herbert L Bonkovsky, MD

Adjunct Professor, University of North Carolina

Professor, University of Connecticut

Disclosure: Grant/Research/Clinical Trial Support: Clinuvel [Porphyria (Afamalanotide)]; Alnylam Pharma; Gilead Sciences [PCT HCV]; Recordati; Mitsubishi-Tanabe [Porphyria (hematin)]. Consultant/Advisory Boards: Alnylam Pharma; Recordati; Mitsubishi-Tanabe [Porphyria (hematin)].

Robert M Bookchin, MD

Professor of Medicine

Albert Einstein College of Medicine

Disclosure: Nothing to disclose

Mark Bower, PhD, FRCP, FRCPath

Professor of Oncology

Imperial College, London

Disclosure: Speaker's Bureau: ViiV, Gilead, MSD, Janssen [HIV-related cancers (siltuximab, rituximab)].

Patrick Brown, MD

Director, Pediatric Leukemia Program

Associate Professor of Oncology and Pediatrics

Sidney Kimmel Comprehensive Cancer Center

Johns Hopkins University School of Medicine

Disclosure: Nothing to disclose

Carlo Brugnara, MD

Professor

Harvard Medical School

Disclosure: Nothing to disclose

Joel Anne Chasis, MD

Associate Professor of Medicine

University of California, San Francisco

Disclosure: Nothing to disclose

Joseph M Connors, MD

Chair, Lymphoma Tumor Group

British Colombia Cancer Agency

Disclosure: Grant/Research/Clinical Trial Support: F Hoffmann-La Roche; Bristol Myers Squibb; Seattle Genetics; Takeda Pharmaceutical Company. Patent Holder: NanoString Technologies.

Claire Dearden, MD, BSc, FRCP, FRCPath

Consultant Haematologist

The Royal Marsden Hospital and Institute of Cancer Research, London

Disclosure: Consultant/Advisory Boards: Roche [B-PLL (Rituximab)]; Gilead [B-PLL (Idelalisib)]; Janssen [B-PLL (Ibrutinib)]; Sanofi [T-PLL (Alemtuzumab)].

Michael R DeBaun, MD, MPH

Professor of Pediatrics and Internal Medicine

Vanderbilt University School of Medicine

Disclosure: Nothing to disclose

Robert J Desnick, MD, PhD

Professor and Chair, Department of Genetics and Genomic Sciences

Mount Sinai School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Alnylam [Acute porphyria (RNAi therapy clinical trial)]; Recordati Rare Diseases. Consultant/Advisory Boards: Alnylam [Acute porphyria (RNAi therapy clinical trial)]; Recordati Rare Diseases. Patent Holder: Alnylam [Acute porphyria (RNAi therapy clinical trial)].

Jonathan W Friedberg, MD

Professor of Medicine

James P Wilmot Cancer Center, University of Rochester

Disclosure: Consultant/Advisory Boards: Bayer [DSMB for trials (Investigational agents)]; Kite [CAR-T cells (Investigational agents)].

Richard R Gammon, MD

Medical Director - OneBlood, Inc.

Assistant Professor of Pathology, University of Central Florida, College of Medicine

Disclosure: Speaker's Bureau: Ortho Clinical Diagnostics [Patient blood management].

Tomas Ganz, MD, PhD

Professor of Medicine and Pathology

David Geffen School of Medicine at UCLA

Disclosure: Grant/Research/Clinical Trial Support: Keryx Pharma [Iron metabolism (Iron Citrate)], Silarus Pharma [Iron metabolism], Akebia [Anemia and iron metabolism]. Consultant/Advisory Boards: Akebia, Vifor Pharma, Intrinsic LifeSciences, La Jolla Pharmaceutical Company, Keryx Pharma, Silarus Pharma [iron metabolism and anemia (IV iron, Iron diagnostics, Minihepcidin, Iron citrate)]. Patent Holder: Multiple assigned to UCLA [Iron metabolism]. Equity Ownership/Stock Options: Intrinsic LifeSciences, Silarus Pharma.

Jason Gotlib, MD, MS

Professor of Medicine

Stanford University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Novartis [Mastocytosis (Midostaurin)]; NIH/NCI [Advanced systemic mastocytosis/mast cell leukemia (Brentuximab vedotin)]; NIH/NCI [Systemic mastocytosis (Ibrutinib)]; Seattle Genetics [Advanced systemic mastocytosis/mast cell leukemia (Brentuximab vedotin)]; Pharmacyclics [Systemic mastocytosis (Ibrutinib)]; Stemline Therapeutics, Inc [High-risk myeloproliferative neoplasms (SL-401)]. Consultant/Advisory Boards: Deciphera Pharmaceuticals [Mastocytosis]; Blueprint Medicines [Mastocytosis]; Plexxikon [Mastocytosis].

Lawrence D Kaplan, MD

Clinical Professor of Medicine

University of California, San Francisco

Disclosure: Nothing to disclose

Youn H Kim, MD

Professor of Dermatology

Stanford University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Esai [CTCL (E7777/denileukin diftitox)], Kyowa Hakko Kirin [CTCL (mogamulizumab)], Merck [CTCL (Pembromulizumab)], Millennium/Takeda [CTCL (brentuximab vedotin)], Seattle Genetics [CTCL (brentuximab vedotin)], Soligenix [CTCL (TOPICAL SGX301)], Tetralogic [CTCL (SHAPE)], Neumedicine [CTCL (Interleukin-12)], Innate [CTCL (IPH4102)], Infinity Pharmaceuticals. Consultant/Advisory Boards: Actelion [CTCL], Celgene [CTCL (Romidepsin)], Eisai [CTCL (E7777/denileukin diftitox)], Galderma [CTCL], Kyowa Hakko Kirin [CTCL (Mogamulizumab)], Millennium/Takeda Pharma [CTCL (Brentuximab Vedotin)], Seattle Genetics [CTCL (Brentuximab Vedotin)], Forty Seven Inc [CTCL], Horizon Pharma [CTCL (Actimmune)], Portola Pharma [CTCL (Cerdulatinib)], miRagen [CTCL (AntimiR-155 MRG-106)], Medivir.

Jonathan E Kolitz, MD

Professor of Medicine

Hofstra Northwell School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Celator [AML (CPX-351)]; Boehringer-Ingelheim [AML (volasertib)]; Millennium [AML, MDS (pevonedistat)]; Cantex [AML (CX-01)]; Erytech Pharma [ALL (ERYASP)]. Equity Ownership/Stock Options (Spouse): Celgene [AML (lenalidomide)]; Amgen [AML, ALL (filgrastim, PEG-filgrastim)]. Consultant/Advisory Boards: Pharmacyclics, Seattle Genetics, Novartis, Gilead. Equity Ownership/Stock Options: Celgene [AML (lenalidomide)]; Amgen [AML, ALL (filgrastim, PEG-filgrastim)].

Marcel Levi, MD, PhD

Chief Executive Officer

University College London Hospitals

Professor of Medicine

Academic Medical Center, University of Amsterdam

Disclosure: Nothing to disclose

Raymond Liang, MD

SH Ho Professor of Hematology and Oncology

University of Hong Kong

Disclosure: Nothing to disclose

Andrew Lister, MD, FRCP, FRCPath, FRCR

Section Editor — Lymphoproliferative Disorders

Professor of Medical Oncology

St. Bartholomew's Hospital, London

Disclosure: Consultant/Advisory Boards: Celgene [malignant lymphoma], Pfizer [Lymphoma (anti-CD20 biosimilars)], Gilead (data monitoring committee) [CLL, indolent lymphoma (idelalisib [CAL 101])], Roche (data monitoring committee) [Indolent lymphoma (obinutuzumab [GA101])], Millennium/Takeda (data monitoring committee) [Hodgkin lymphoma (brentuximab vedotin)]; Merck (pembrolizumab). Equity Ownership/Stock Options (Spouse also): GSK; Johnson & Johnson; AstraZeneca; Novartis; Pfizer; Hikma Pharma.

Thomas P Loughran, Jr, MD

Director, University of Virginia Cancer Center

University of Virginia

Disclosure: Nothing to disclose

Silvia Montoto, MD

Senior Lecturer, Honorary Consultant

Barts and The London School of Medicine and Dentistry

Disclosure: Speaker's Bureau: Roche [NHL (rituximab)]. Other Financial Interest: Gilead [travel support, NHL (idelalisib)].

Peter Newburger, MD

Section Editor — White Blood Cell Disorders

Ali and John Pierce Professor of Pediatric Hematology/Oncology

University of Massachusetts Medical School

Disclosure: Nothing to disclose

Enrico M Novelli, MD, MS

Assistant Professor of Medicine, University of Pittsburgh

Medical Director, UPMC Adult Sickle Cell Anemia Program

Disclosure: Nothing to disclose

Ruth F Padmore, MD, FRCPC, PhD

Staff Hematopathologist, The Ottawa Hospital and Eastern Ontario Regional Laboratory Association

Associate Professor, University of Ottawa

Disclosure: Nothing to disclose

German A Pihan, MD

Chief Diagnostic Hematopathology Service, Beth Israel Deaconess Medical Center

Assistant Professor of Pathology, Harvard Medical School

Disclosure: Nothing to disclose

Josef T Prchal, MD

Professor of Medicine

University of Utah

Disclosure: Nothing to disclose

Andreas Rosenwald, MD

Professor, Institute of Pathology

University of Würzburg, Germany

Disclosure: Nothing to disclose

Mohammed Salhab, MD

Hematology/Oncology Fellow

University of Massachusetts Medical School

Disclosure: Nothing to disclose

Vaishali Sanchorawala, MD

Professor of Medicine

Director, Autologous Stem Cell Transplant Program

Director, Amyloidosis Center

Boston Medical Center and Boston University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Prothena [AL amyloidosis (NEOD001)], Takeda [AL amyloidosis (ixazomib)]. Consultant/Advisory Boards: Caelum [AL amyloidosis (11-1F4)].

Stanley L Schrier, MD

Editor-in-Chief — Hematology

Section Editor — Myeloproliferative Disorders; Red Blood Cell Disorders

Professor of Medicine

Stanford University School of Medicine

Disclosure: Nothing to disclose

Detlef Schuppan, MD, PhD

Professor of Medicine, Harvard Medical School

Institute for Translational Immunology

Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University, Mainz, Germany, Division of Gastroenterology

Disclosure: Patent Holder: Eurospital [Celiac disease (TG2-antibody)]; Consultant/Advisory Boards: Takeda [Celiac disease (Celiac disease drug development)].

Arthur J Silvergleid, MD

Section Editor — Transfusion Medicine

Affiliate Associate Professor, Department of Pathology and Cell Biology

University of South Florida, College of Medicine

Medical Director, OneBlood, Inc.

Disclosure: Nothing to disclose

Martin S Tallman, MD

Chief, Leukemia Service, Memorial Sloan-Kettering Cancer Center

Professor of Medicine

Weill Cornell Medical College

Disclosure: Nothing to disclose

Douglas M Tollefsen, MD

Professor of Medicine

Washington University School of Medicine

Disclosure: Nothing to disclose

Guido J Tricot, MD, PhD

Professor of Medicine, Director of BMT and Myeloma Program

University of Iowa

Disclosure: Nothing to disclose

Richard A Van Etten, MD, PhD

Professor of Medicine

University of California, Irvine

Disclosure: Nothing to disclose

Michael R Verneris, MD

Associate Professor, Pediatric Hematology/Oncology and Blood and Marrow Transplant

University of Minnesota

Disclosure: Nothing to disclose

Ravi Vij, MD, MBA

Professor of Medicine

Washington University School of Medicine

Disclosure: Grant/Research/Clinical Trial Support: Amgen, Takeda [multiple myeloma]. Consultant/Advisory Boards: Celgene, Takeda, BMS, Janssen, Abbvie, Amgen, Karyopharm [multiple myeloma].

John R Wingard, MD

Professor of Medicine

University of Florida College of Medicine

Disclosure: Speaker's Bureau: Pfizer [fungal infections and management (antifungal drugs)]. Consultant/Advisory Boards: Astellas [CMV, antifungal drugs]; Ansun, Gilead [respiratory virus antivirals]; Merck [CMV, antifungal drugs].

Ann K Wittkowsky, PharmD, CACP, FASHP, FCCP

Clinical Professor

University of Washington School of Pharmacy

Disclosure: Nothing to disclose

Yanyun Wu, MD, PhD

Chief Medical Officer

Puget Sound Blood Center

Disclosure: Nothing to disclose

James L Zehnder, MD

Professor of Pathology and Medicine (Hematology)

Stanford University School of Medicine

Disclosure: Consultant/Advisory Boards: Novo Nordisk [Hemostasis testing methods]; Novartis [Thrombopoietin agonists (Eltrombopag)]; Instrumentation Laboratory [laboratory instrumentation (hemostasis testing methods)].